3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop

With aducanumab no longer a contender, which drugs are the leaders in the race to develop an effective treatment for Alzheimer's disease? Probably the top candidates are experimental drugs being developed by Avanir Pharmaceuticals, which is owned by Otsuka Holdings (NASDAQOTH:OTSKY), Axsome Therapeutics (NASDAQ: AXSM), Amgen (NASDAQ: AMGN), and Novartis (NYSE: NVS). Here's a quick update on these leading Alzheimer's disease drugs in development.